$BICX
BioCorRx Inc. Stock $bicx

$bicx Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000147793224007148 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$0.00	$10.15K
YoY Change		-100.0%	-89.26%
Cost Of Revenue		$0.00	$3.881K
YoY Change		-100.0%	65.64%
Gross Profit		$0.00	$6.264K
YoY Change		-100.0%	-93.2%
Gross Profit Margin			61.74%
Selling, General & Admin		$1.193M	$674.5K
YoY Change		76.86%	-12.61%
% of Gross Profit			10767.18%
Research & Development		$460.1K	$287.0K
YoY Change		60.35%	-16.23%
% of Gross Profit			4581.13%
Depreciation & Amortization		$6.420K	$6.419K
YoY Change		0.02%	-2.27%
% of Gross Profit			102.47%
Operating Expenses		$1.660M	$972.0K
YoY Change		70.75%	-13.49%
Operating Profit		-$1.660M	-$961.9K
YoY Change		72.55%	-6.54%
Interest Expense		$149.0K	$36.88K
YoY Change		303.98%	170.72%
% of Operating Profit
Other Income/Expense, Net		$146.7K	$94.52K
YoY Change		55.22%	20.99%
Pretax Income		-$1.513M	-$867.3K
YoY Change		74.44%	-8.8%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings		-$1.513M	-$867.3K
YoY Change		74.44%	-8.8%
Net Earnings / Revenue			-8549.51%
Basic Earnings Per Share
Diluted Earnings Per Share			-$0.10
COMMON SHARES
Basic Shares Outstanding	12.75M shares	10.89M shares	8.525M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$160.0K
YoY Change		309.21%
Cash & Equivalents	$90.00	$156.4K
Short-Term Investments
Other Short-Term Assets		$70.00K
YoY Change		-45.27%
Inventory
Prepaid Expenses	$38.84K	$72.17K
Receivables	$0.00	$12.22K
Other Receivables		$0.00
Total Short-Term Assets	$353.1K	$245.8K
YoY Change	43.66%	-26.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$31.69K	$57.36K
YoY Change	-44.76%	-31.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$40.00K
YoY Change		-10.15%
Total Long-Term Assets	$290.5K	$288.7K
YoY Change	0.63%	-40.63%
TOTAL ASSETS
Total Short-Term Assets	$353.1K	$245.8K
Total Long-Term Assets	$290.5K	$288.7K
Total Assets	$643.6K	$534.4K
YoY Change	20.42%	-34.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.096M	$2.390M
YoY Change	29.55%	88.59%
Accrued Expenses		$2.200M
YoY Change		35.18%
Deferred Revenue
YoY Change
Short-Term Debt		$1.350M
YoY Change		48.91%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.224M	$5.947M
YoY Change	38.3%	32.32%
LONG-TERM LIABILITIES
Long-Term Debt		$70.00K
YoY Change		-5.65%
Other Long-Term Liabilities		$3.780M
YoY Change		9.53%
Total Long-Term Liabilities		$3.850M
YoY Change		9.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.224M	$5.947M
Total Long-Term Liabilities		$3.850M
Total Liabilities	$12.65M	$9.795M
YoY Change	29.12%	22.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$82.04M	-$77.13M
YoY Change	6.37%	5.41%
Common Stock	$11.21K	$8.592K
YoY Change	30.49%	12.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$11.83M	-$9.132M
YoY Change
Total Liabilities & Shareholders Equity	$643.6K	$534.4K
YoY Change	20.42%	-34.76%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$1.513M	-$867.3K
YoY Change	74.44%	-8.8%
Depreciation, Depletion And Amortization	$6.420K	$6.419K
YoY Change	0.02%	-2.27%
Cash From Operating Activities		-$350.0K
YoY Change		-4.84%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		310.0K
YoY Change		-3.09%
NET CHANGE
Cash From Operating Activities		-350.0K
Cash From Investing Activities
Cash From Financing Activities		310.0K
Net Change In Cash		-40.00K
YoY Change		-16.54%
FREE CASH FLOW
Cash From Operating Activities		-$350.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	390	usd
CY2024Q3	us-gaap	Investment Company Dividend Distribution InvestmentCompanyDividendDistribution	0	usd
CY2023Q3	us-gaap	Investment Company Dividend Distribution InvestmentCompanyDividendDistribution	8817	usd
CY2024Q3	bicx	Membership Program Fees MembershipProgramFees	0	usd
CY2023Q3	bicx	Membership Program Fees MembershipProgramFees	938	usd
CY2024Q3	us-gaap	Revenues Revenues	0	usd
CY2023Q3	us-gaap	Revenues Revenues	10145	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	61072	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	4045	usd
CY2024Q3	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	18511	usd
CY2024Q3	bicx	Prepaid Subscription Services PrepaidSubscriptionServices	8546	usd
CY2023Q4	bicx	Prepaid Subscription Services PrepaidSubscriptionServices	26380	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	53460	usd
CY2023Q4	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	53460	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	38837	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	44891	usd
	bicx	Shares Underlying Options Outstanding SharesUnderlyingOptionsOutstanding	891443	usd
	bicx	Shares Underlying Warrants Outstanding SharesUnderlyingWarrantsOutstanding	1765856	shares
	bicx	Shares Underlying Warrants Outstanding SharesUnderlyingWarrantsOutstanding	1150856	shares
	bicx	Convertible Preferred Stock Outstanding ConvertiblePreferredStockOutstanding	240000	shares
	bicx	Convertible Preferred Stock Outstanding ConvertiblePreferredStockOutstanding	240000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3099481	shares
CY2019Q1	bicx	Funding During Second Year FundingDuringSecondYear	2831838	usd
CY2019Q1	bicx	Grant Funding During The Third Year GrantFundingDuringTheThirdYear	3453367	usd
CY2019Q1	bicx	Grant Additional Funding During The Third Year GrantAdditionalFundingDuringTheThirdYear	99431	usd
CY2023Q4	bicx	Grant Receivables GrantReceivables	76266	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	61072	usd
CY2024Q3	bicx	Working Capital Deficiency WorkingCapitalDeficiency	-7871228	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-849084	usd
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	30291	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	194551	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	162866	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	143608	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31685	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50943	usd
	us-gaap	Depreciation Depreciation	19258	usd
	us-gaap	Depreciation Depreciation	19209	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	500333	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39266	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	122732	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	249993	usd
CY2024Q3	bicx	Present Value Discount PresentValueDiscount	-41284	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	4351	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3096150	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2473457	usd
CY2024Q3	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	1330133	usd
CY2023Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	1268264	usd
CY2024Q3	bicx	Interest Payable On Notes Payable Related Parties InterestPayableOnNotesPayableRelatedParties	583530	usd
CY2023Q4	bicx	Interest Payable On Notes Payable Related Parties InterestPayableOnNotesPayableRelatedParties	478920	usd
CY2024Q3	bicx	Deferred Insurance Costs DeferredInsuranceCosts	24198	usd
CY2023Q4	bicx	Deferred Insurance Costs DeferredInsuranceCosts	0	usd
CY2023Q4	bicx	Interest Payable On Eidl Loan InterestPayableOnEidlLoan	5675	usd
CY2023Q4	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	43321	usd
CY2024Q3	bicx	Accrued Expenses AccruedExpenses	176711	usd
CY2023Q4	bicx	Accrued Expenses AccruedExpenses	57542	usd
CY2024Q3	bicx	Advances From A Third Party AdvancesFromAThirdParty	21480	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	148999	usd
CY2024Q3	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	1330133	usd
CY2023Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	1268264	usd
CY2023Q4	bicx	Outstanding Notes Payables To Related Parties OutstandingNotesPayablesToRelatedParties	999088	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	187119	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31685	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50943	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	208709	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	97278	usd
CY2023Q4	bicx	Due To Related Party DueToRelatedParty	1683453	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5681787	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4649179	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	39266	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	122732	usd
CY2024Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	53460	usd
CY2024Q3	bicx	Debt Discount On Notes Payable DebtDiscountOnNotesPayable	20790	usd
CY2023Q4	bicx	Debt Discount On Notes Payable DebtDiscountOnNotesPayable	354730	usd
CY2024Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1288290	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	606750	usd
CY2024Q3	bicx	Debt Discount Related Parties DebtDiscountRelatedParties	0	usd
CY2023Q4	bicx	Debt Discount Related Parties DebtDiscountRelatedParties	77295	usd
CY2024Q3	bicx	Notes Payables Related Parties Classified Current NotesPayablesRelatedPartiesClassifiedCurrent	1214982	usd
CY2023Q4	bicx	Notes Payables Related Parties Classified Current NotesPayablesRelatedPartiesClassifiedCurrent	999088	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4045	usd
CY2024Q3	us-gaap	Liabilities Liabilities	12646789	usd
CY2023Q4	us-gaap	Liabilities Liabilities	10341411	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	600000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11211595	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8674029	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	11212	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8674	usd
CY2024Q3	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	100000	usd
CY2023Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	100009	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	70080274	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68149029	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-82044527	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78103018	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-11831425	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-9823690	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	-171794	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-128834	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-12003219	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9952524	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	643570	usd
CY2024Q3	us-gaap	Revenues Revenues	0	usd
CY2023Q3	us-gaap	Revenues Revenues	10145	usd
	us-gaap	Revenues Revenues	70222	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	3881	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1667	usd
	us-gaap	Cost Of Revenue CostOfRevenue	22933	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	460138	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	286962	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1210334	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	762768	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1192869	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	674456	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2773288	usd
CY2023Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	47980	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	1659721	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	972013	usd
	us-gaap	Operating Expenses OperatingExpenses	4005430	usd
	us-gaap	Operating Expenses OperatingExpenses	3035306	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1659721	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-961868	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3997765	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2965084	usd
	us-gaap	Interest Expense InterestExpense	648726	usd
	us-gaap	Interest Expense InterestExpense	90412	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-123563	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-123563	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-34338	usd
CY2024Q3	bicx	Grant Income GrantIncome	572777	usd
CY2023Q3	bicx	Grant Income GrantIncome	300985	usd
	bicx	Grant Income GrantIncome	1204407	usd
	bicx	Grant Income GrantIncome	790140	usd
CY2024Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4763	usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	129822	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	146711	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	94520	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13296	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Noninterest Income NoninterestIncome	25623	usd
CY2023Q3	us-gaap	Noninterest Income NoninterestIncome	1068	usd
	us-gaap	Noninterest Income NoninterestIncome	42960	usd
	us-gaap	Noninterest Income NoninterestIncome	3108	usd
CY2024Q3	bicx	Income Loss Attributables To Parent IncomeLossAttributablesToParent	-1487387	usd
CY2023Q3	bicx	Income Loss Attributables To Parent IncomeLossAttributablesToParent	-866280	usd
	bicx	Income Loss Attributables To Parent IncomeLossAttributablesToParent	-3941509	usd
	bicx	Income Loss Attributables To Parent IncomeLossAttributablesToParent	-2798373	usd
CY2024Q3	bicx	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.14
CY2023Q3	bicx	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.10
	bicx	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.41
	bicx	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.34
CY2024Q3	bicx	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	10908291	shares
CY2023Q3	bicx	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	8537320	shares
	bicx	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	9712939	shares
	bicx	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	8250725	shares
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	20142	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	20093	usd
	bicx	Amortization Of Discount On Royalty Obligation AmortizationOfDiscountOnRoyaltyObligation	358882	usd
	bicx	Amortization Of Discount On Royalty Obligation AmortizationOfDiscountOnRoyaltyObligation	355662	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	519781	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	61094	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	47980	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	52579	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	92952	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-123563	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-34338	usd
	us-gaap	Other Income OtherIncome	32405	usd
	us-gaap	Other Income OtherIncome	0	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	933721	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	238792	usd
	bicx	Increase Decrease In Grant Receivable IncreaseDecreaseInGrantReceivable	237904	usd
	bicx	Increase Decrease In Grant Receivable IncreaseDecreaseInGrantReceivable	-125161	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	6054	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	10593	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1448266	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	597505	usd
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	2584	usd
	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-56573	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-99134	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4045	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-26164	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-849084	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1319446	usd
	bicx	Proceeds From Common Stock Subscription And Royalty Agreement ProceedsFromCommonStockSubscriptionAndRoyaltyAgreement	0	usd
	bicx	Proceeds From Common Stock Subscription And Royalty Agreement ProceedsFromCommonStockSubscriptionAndRoyaltyAgreement	900000	usd
	bicx	Payment To Economic Injury Disaster Loan PaymentToEconomicInjuryDisasterLoan	1073	usd
	bicx	Payment To Economic Injury Disaster Loan PaymentToEconomicInjuryDisasterLoan	1033	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	9000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	35000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	200000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	594025	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	343273	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	783952	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1407240	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-65132	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	87794	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65222	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68615	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	156409	usd
	us-gaap	Interest Paid Net InterestPaidNet	10007	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	bicx	Warrants Issued In Connection With Issuance Of Promissory Notes WarrantsIssuedInConnectionWithIssuanceOfPromissoryNotes	83552	usd
	bicx	Warrants Issued In Connection With Issuance Of Promissory Notes WarrantsIssuedInConnectionWithIssuanceOfPromissoryNotes	176545	usd
	bicx	Derivative Liabilities Recognized In Connection With Issuance Of Promissory Notes DerivativeLiabilitiesRecognizedInConnectionWithIssuanceOfPromissoryNotes	0	usd
	bicx	Derivative Liability Recognized In Connection With Issuance Of Promissory Notes DerivativeLiabilityRecognizedInConnectionWithIssuanceOfPromissoryNotes	809284	usd
	bicx	Derivative Liability Recognized In Connection With Issuance Of Promissory Notes DerivativeLiabilityRecognizedInConnectionWithIssuanceOfPromissoryNotes	361892	usd
	bicx	Common Stock Issued In Connection With Subscription Agreement CommonStockIssuedInConnectionWithSubscriptionAgreement	9	usd
	bicx	Common Stock Issued In Connection With Subscription Agreement CommonStockIssuedInConnectionWithSubscriptionAgreement	0	usd
	bicx	Record Right To Use Assets Per Asc842 RecordRightToUseAssetsPerAsc842	0	usd
	bicx	Record Lease Liability Per Asc842 RecordLeaseLiabilityPerAsc842	225663	usd
	bicx	Record Lease Liability Per Asc842 RecordLeaseLiabilityPerAsc842	0	usd
	bicx	Common Stock Issued In Connection With Issuance Of Promissory Notes CommonStockIssuedInConnectionWithIssuanceOfPromissoryNotes	107217	usd
	bicx	Common Stock Issued In Connection With Issuance Of Promissory Notes CommonStockIssuedInConnectionWithIssuanceOfPromissoryNotes	65580	usd
CY2024Q3	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	0	usd
	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	2205	usd
	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	10645	usd
	bicx	Membership Program Fees MembershipProgramFees	1415	usd
	bicx	Membership Program Fees MembershipProgramFees	7596	usd
	us-gaap	Revenues Revenues	7665	usd
	us-gaap	Revenues Revenues	70222	usd
CY2023Q4	bicx	Deferred Revenue Short Term DeferredRevenueShortTerm	0	usd
CY2023Q4	bicx	Deferred Revenue Short Term89 DeferredRevenueShortTerm89	4045	usd
CY2024Q3	bicx	Recognizedsaleof Net RecognizedsaleofNet	-4045	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include assumptions used in the fair value of other equity and debt instruments, income taxes, loss contingencies, and research and development costs.</p>
	bicx	Description Aging Categories To Estimates Risk DescriptionAgingCategoriesToEstimatesRisk	The Company used the following aging categories to estimate the risk of delinquency status: (i) 0 days past due; (ii) 1-30 days past due; (iii) 31-60 days past due; (iv) 61-90 days past due; and (v) over 90 days past due
CY2021Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	47980	usd
	bicx	Shares Underlying Options Outstanding SharesUnderlyingOptionsOutstanding	1093625	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2282299	shares
CY2024Q3	us-gaap	Advertising Expense AdvertisingExpense	5868	usd
CY2023Q3	us-gaap	Advertising Expense AdvertisingExpense	25846	usd
	us-gaap	Advertising Expense AdvertisingExpense	30076	usd
	us-gaap	Advertising Expense AdvertisingExpense	88633	usd
CY2019Q1	bicx	Funding During First Year FundingDuringFirstYear	2842430	usd
CY2024Q2	bicx	Grant Funding GrantFunding	11029977	usd
CY2024Q2	bicx	Funding During First Year FundingDuringFirstYear	4131123	usd
CY2024Q2	bicx	Funding During Second Year FundingDuringSecondYear	3638268	usd
CY2024Q2	bicx	Grant Funding During The Third Year GrantFundingDuringTheThirdYear	3260586	usd
CY2024Q3	bicx	Grant Receivables GrantReceivables	314170	usd
CY2023Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	0	usd
CY2024Q3	bicx	Grant Income GrantIncome	572777	usd
CY2023Q3	bicx	Grant Income GrantIncome	300985	usd
	bicx	Grant Income GrantIncome	1204407	usd
	bicx	Grant Income GrantIncome	790140	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	460138	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	286962	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1210334	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	762768	usd
	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.50	pure
	bicx	Description Of Non Controlling Interest DescriptionOfNonControllingInterest	Due to a management fee equal to 65% of the Medical Corporation’s gross collected monthly revenue, 65% of the Medical Corporation’s earnings was allocated to the Company, and 35% to the non-controlling interest. Due to the Company’s retaining 75.8% ownership of BioCorRx Pharmaceuticals, Inc., 75.8% of BioCorRx Pharmaceuticals, Inc
	bicx	Royalty Obligations Net Policy Textblock RoyaltyObligationsNetPolicyTextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued. In order to record the discount of the liability, the Company fair valued the royalty and the difference between fair value of the royalty obligation and the gross projected future payments was $7,171,200 and was recorded as non-cash interest expense over the life of the liability and offset to additional paid in capital at inception.</p>
	bicx	Royalty Obligations Description RoyaltyObligationsDescription	The Company accounted for royalty obligations as debt in accordance with ASC 470-10-25 and derived a debt discount, which is amortized using the straight line method over the expected life of the arrangement, which is 15 years. The Company has no obligation to repay the then outstanding balance if during the expected life of 15 years the treatment is discontinued. In order to record the discount of the liability, the Company fair valued the royalty and the difference between fair value of the royalty obligation
	us-gaap	Royalty Expense RoyaltyExpense	7171200	usd
CY2024Q3	us-gaap	Cash Cash	90	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	194551	usd
CY2024Q3	us-gaap	Depreciation Depreciation	6420	usd
CY2023Q3	us-gaap	Depreciation Depreciation	6419	usd
CY2024Q2	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2029-04-30
CY2024Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	4545	usd
CY2024Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	225663	usd
	bicx	Recognized On Other Income Expense RecognizedOnOtherIncomeExpense	32405	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	13636	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	54544	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	54544	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	54544	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	54544	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	18181	usd
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	13636	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	34522	usd
CY2024Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	13636	usd
CY2023Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	34522	usd
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	107326	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	107326	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	65066	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	113508	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	285	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1169	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1169	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1169	usd
CY2024Q3	bicx	Interest Payable On Eidl Loan InterestPayableOnEidlLoan	5572	usd
CY2024Q3	bicx	Payables To Customers Payroll PayablesToCustomersPayroll	62816	usd
CY2024Q3	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	0	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5681787	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4649179	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	36883	usd
	us-gaap	Interest Expense InterestExpense	648726	usd
	us-gaap	Interest Expense InterestExpense	90412	usd
	bicx	Notes Payable Related Parties Disclosure Textblock NotesPayableRelatedPartiesDisclosureTextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">NOTE 10 - NOTES PAYABLE-RELATED PARTIES</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2024 and December 31, 2023, the Company had advances from Kent Emry (Chairman of the Company). The balance outstanding as of September 30, 2024 and December 31, 2023 was $1,500.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 22, 2013, the Company issued an unsecured promissory note payable to Kent Emry (Chairman of the Board) for $200,000 due January 1, 2018, with a stated interest rate of 12% per annum beginning three months from issuance, payable monthly. Principal payments were due starting February 1, 2015 at $6,650 per month. The lender has an option to convert the note to licensing rights for the State of Oregon. The Company currently is in default of the principal and interest. The balance outstanding as of September 30, 2024 and December 31, 2023 was $163,610.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 9, 2021, the Company issued an unsecured promissory note payable to Kent Emry for $500,000 with principal and interest due June 8, 2022, with a stated interest rate of 25% per annum. The balance outstanding as of September 30, 2024 and December 31, 2023 is $500,000. The interest expense during the three months ended September 30, 2024 and 2023 were $31,507. The interest expense during the nine months ended September 30, 2024 and 2023 were $93,835 and $93,493, respectively. If the Company fails to make any payment due under the terms of the promissory note, the Company shall issue a warrant to Kent Emry to which the number of common shares that Kent Emry has the right to purchase equals 119,617 common shares. The warrant shall have a term of three years with an exercise price of $4.14 and shall be equitably adjusted to offset the effect of any stock splits and similar events. On June 8, 2022, the Company issued the warrant that entitles Kent Emry to purchase 119,617 common shares due to the loan default. The fair value of the warrant on June 8, 2022 was $214,975, which the Company recognized as interest expense - related party.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since September 2022, the Company had received an aggregate of $296,426 advances from Louis C Lucido, a member of the Company’s Board of Directors. On August 29, 2023, the Company issued an unsecured promissory note payable to Louis C Lucido for $150,000 with principal and interest due August 29, 2024, with a stated interest rate of 8% per annum. The promissory note, together with all accrued interest, shall be converted into common shares at a conversion price of $2.00 per share on or before August 29, 2024. The interest expense during the three months ended September 30, 2024 was $0. The interest expense during the nine months ended September 30, 2024 was $3,781. In connection with the issuance of the promissory note, the Company issued the warrant that entitles Mr. Lucido to purchase 150,000 common shares. The warrant shall have a term of three years with an exercise price of $2.00 and shall be equitably adjusted to offset the effect of any stock splits and similar events. The Company allocated the proceeds based on the relative fair value of the debt and the warrants, resulting in the recognition of $87,724 of debt discount on such promissory note. As additional consideration for the debt, the Company issued 18,000 shares of common stock valued at $29,340, which was also recognized as debt discount. During the three months ended September 30, 2024, the Company amortized $0 of debt discount as interest expense. During the nine months ended September 30, 2024, the Company amortized $77,295 of debt discount as interest expense. On April 24, 2024, the Company entered into an Exchange Agreement (the “Louis 2024 Exchange Agreement”) with Mr. Lucido, pursuant to which Mr. Lucido agreed to exchange of the promissory note then outstanding of $446,426 and the accrued interest on the promissory note of $7,858 and director fees of $90,000 into the Company’s 460,477 shares of common stock at a price of $1.18 per share based on the underlying market value of the common stock at the date of issuance. As of September 30, 2024 and December 31, 2023, the outstanding balance of advances from Mr. Lucido and promissory notes issued to Mr. Lucido was $0 and $275,000, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 1, 2022, the Company issued an unsecured promissory note payable to Louis C Lucido for $300,000 with principal and interest due November 1, 2023, with a stated interest rate of 5% per annum. Under the terms of the note the Company shall pay quarterly interest payments of $3,750. On April 3, 2023, the Company entered into the Louis 2023 Exchange Agreement, pursuant to which Mr. Lucido agreed to exchange of the promissory note then outstanding of $300,000 and the accrued interest on the promissory note of $13,892 into the Company’s 183,606 shares of common stock at a price of $1.71 per share based on the underlying market value of the common stock at the date of issuance, resulting in the recognition of $34,338 of loss on settlement of debt. The balance outstanding as of September 30, 2024 and December 31, 2023 was $0. As the Company failed to make a payment due under the terms of the promissory note, the stated interest rate of the note was increased to 20% on February 1, 2023. The interest expense during the three months ended September 30, 2024 and 2023 was $0 . The interest expense during the nine months ended September 30, 2024 and 2023 was $0 and $11,386, respectively. As additional consideration for the loan the Company issued 33,000 shares of common stock and valued at $59,400, which was recognized as debt discount. During the three months ended September 30, 2024 and 2023, the Company amortized $0 of debt discount as interest expense. During the nine months ended September 30, 2024 and 2023, the Company amortized $0 and $15,135, respectively, of debt discount as interest expense. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the third quarter of 2024, the Company received an aggregate of $265,100 advances from Louis C Lucido.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2024 and December 31, 2023, the Company owed $284,772 and $136,273 advances to Lourdes Felix. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The interest expense – related parties during the three months ended September 30, 2024 and 2023 were $158,267 and $169,582, respectively, which includes the amortization of royalty obligations as interest expense of $121,774 (see Note 12). The interest expense – related parties during the nine months ended September 30, 2024 and 2023 were $548,644 and $501,787, respectively, which includes the amortization of royalty obligations as interest expense of $358,882 and $355,662, respectively (see Note 12). As of September 30, 2024 and December 31, 2023, the accumulated interest on related parties notes payable was $583,530 and $478,920, respectively, and was included in accounts payable and accrued expenses on the balance sheet. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The outstanding notes payables to related parties as of September 30, 2024 and December 31, 2023 were summarized as below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September</strong><strong> 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Advances from Kent Emry</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">1,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">1,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Advances from Louis C Lucido</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">265,100</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">125,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Advances from Lourdes Felix</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">284,772</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">136,273</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Promissory notes payables to Kent Emry</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">663,610</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">663,610</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Promissory note payable to Louis C Lucido, net of debt discount of $0 and $77,295, respectively</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">72,705</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">1,214,982</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">999,088</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2024Q3	bicx	Interest Expenses Related Party InterestExpensesRelatedParty	158267	usd
CY2023Q3	bicx	Interest Expenses Related Party InterestExpensesRelatedParty	169582	usd
	bicx	Interest Expenses Related Party InterestExpensesRelatedParty	548644	usd
	bicx	Interest Expenses Related Party InterestExpensesRelatedParty	501787	usd
CY2024Q3	bicx	Accumulated Interest Notes Payable AccumulatedInterestNotesPayable	583530	usd
CY2023Q4	bicx	Accumulated Interest Notes Payable AccumulatedInterestNotesPayable	478920	usd
CY2024Q3	bicx	Outstanding Notes Payables To Related Parties OutstandingNotesPayablesToRelatedParties	1214982	usd
CY2024Q3	bicx	Accumulated Interest On Eidl Loan AccumulatedInterestOnEidlLoan	5572	usd
CY2023Q4	bicx	Accumulated Interest On Eidl Loan AccumulatedInterestOnEidlLoan	5675	usd
CY2024Q3	us-gaap	Capital Leases Future Minimum Payments Receivable Next Rolling Twelve Months CapitalLeasesFutureMinimumPaymentsReceivableNextRollingTwelveMonths	0	usd
CY2024Q3	us-gaap	Capital Leases Future Minimum Payments Receivable Due In Rolling Year Two CapitalLeasesFutureMinimumPaymentsReceivableDueInRollingYearTwo	0	usd
CY2024Q3	us-gaap	Capital Leases Future Minimum Payments Receivable Due In Rolling Year Three CapitalLeasesFutureMinimumPaymentsReceivableDueInRollingYearThree	16	usd
CY2024Q3	us-gaap	Capital Leases Future Minimum Payments Receivable Due In Rolling Year Four CapitalLeasesFutureMinimumPaymentsReceivableDueInRollingYearFour	1598	usd
CY2024Q3	us-gaap	Capital Leases Future Minimum Payments Receivable Due In Rolling After Year Five CapitalLeasesFutureMinimumPaymentsReceivableDueInRollingAfterYearFive	69779	usd
CY2024Q3	us-gaap	Capital Leases Future Minimum Payments Receivable CapitalLeasesFutureMinimumPaymentsReceivable	71393	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	600000	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	95350	usd
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11211595	shares
	bicx	Share Based Goods And Nonemployee Services Transactions Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionsValuationMethodExpectedTerm1	P5Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	891443	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.41
	bicx	Outstanding Beginning OutstandingBeginning	P3Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	19167	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.92
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	221349	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.52
	bicx	Sharebased Compensation Arrangement By Sharebased Payment Grant In Period SharebasedCompensationArrangementBySharebasedPaymentGrantInPeriod	P4Y9M18D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1093625	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.02
	bicx	Outstanding At Ending OutstandingAtEnding	P2Y9M18D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1093625	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.02
	bicx	Exercisable At End Of Year ExercisableAtEndOfYear	P2Y9M18D
CY2024Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.32
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29261	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16205	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	108191	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48232	usd
CY2024Q3	bicx	Notes Payables Related Parties Current And Noncurrent NotesPayablesRelatedPartiesCurrentAndNoncurrent	1292381	usd
CY2023Q4	bicx	Notes Payables Related Parties Current And Noncurrent NotesPayablesRelatedPartiesCurrentAndNoncurrent	1683453	usd
	bicx	Schedule Of Changes In Non Controlling Interesttabletextblock ScheduleOfChangesInNonControllingInteresttabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance, December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(128,834 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss attributable to the non-controlling interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(42,960 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance, September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(171,794 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance, December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(125,257 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss attributable to the non-controlling interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,108 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance, September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(128,365 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table>
	bicx	Non Controlling Interest Beginning Balance NonControllingInterestBeginningBalance	-128834	usd
	bicx	Net Loss Attributable To The Non Controlling Interest NetLossAttributableToTheNonControllingInterest	-42960	usd
	bicx	Non Controlling Interest Ending Balance NonControllingInterestEndingBalance	-171794	usd
	bicx	Non Controlling Interest Beginning Balance NonControllingInterestBeginningBalance	-125257	usd
	bicx	Net Loss Attributable To The Non Controlling Interest NetLossAttributableToTheNonControllingInterest	-3108	usd
	bicx	Non Controlling Interest Ending Balance NonControllingInterestEndingBalance	-128365	usd
CY2022Q1	bicx	First Payment Owed FirstPaymentOwed	145000	usd
CY2024Q3	us-gaap	Deferred Compensation Arrangement With Individual Cash Award Granted Amount DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount	3500	usd
CY2024Q3	us-gaap	Litigation Reserve LitigationReserve	332503	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001443863
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q3	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2023Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2024Q3	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	0	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023Q4	bicx	Advances From A Third Party AdvancesFromAThirdParty	21480	usd
CY2023Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	121774	usd
CY2023Q3	bicx	Adjustment For Amortization21 AdjustmentForAmortization21	0	usd
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-54208
	dei	Entity Registrant Name EntityRegistrantName	BioCorRx Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0967447
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2390 East Orangewood Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 570
	dei	Entity Address City Or Town EntityAddressCityOrTown	Anaheim
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92806
	dei	City Area Code CityAreaCode	714
	dei	Local Phone Number LocalPhoneNumber	462-4880
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12748896	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65222	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	740	usd
CY2024Q3	us-gaap	Grants Receivable GrantsReceivable	314170	usd
CY2023Q4	us-gaap	Grants Receivable GrantsReceivable	76266	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	38837	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	44891	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	353097	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8143	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9027	usd
CY2024Q3	us-gaap	Deposit Assets DepositAssets	41936	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	44520	usd
CY2024Q3	us-gaap	Other Assets OtherAssets	50079	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	53547	usd
CY2024Q3	us-gaap	Assets Assets	643570	usd
CY2023Q4	us-gaap	Assets Assets	388887	usd
CY2024Q3	bicx	Due To Related Party DueToRelatedParty	1292381	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8224325	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6431209	usd
CY2024Q3	bicx	Economic Injury Disaster Loan Long Term EconomicInjuryDisasterLoanLongTerm	71393	usd
CY2023Q4	bicx	Economic Injury Disaster Loan Long Term EconomicInjuryDisasterLoanLongTerm	72466	usd
CY2024Q3	bicx	Discount On Royalty Obligation Related Parties DiscountOnRoyaltyObligationRelatedParties	4540472	usd
CY2023Q4	bicx	Discount On Royalty Obligation Related Parties DiscountOnRoyaltyObligationRelatedParties	4899354	usd
CY2024Q3	us-gaap	Contractual Obligation ContractualObligation	4181628	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	3822746	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	169443	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10945	usd
CY2024Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	388887	usd
	us-gaap	Revenues Revenues	7665	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2181532	usd
CY2024Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2024Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	6714	usd
CY2023Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	6714	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	20141	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	20093	usd
CY2024Q3	bicx	Interest Expense Related Party Transactions InterestExpenseRelatedPartyTransactions	158267	usd
CY2023Q3	bicx	Interest Expense Related Party Transactions InterestExpenseRelatedPartyTransactions	169582	usd
	bicx	Interest Expense Related Party Transactions InterestExpenseRelatedPartyTransactions	548644	usd
	bicx	Interest Expense Related Party Transactions InterestExpenseRelatedPartyTransactions	501787	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	148999	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	36883	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	163603	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1513010	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-867348	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3984469	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2801481	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-1513010	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-867348	usd
	us-gaap	Profit Loss ProfitLoss	-3984469	usd
	us-gaap	Profit Loss ProfitLoss	-2801481	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9952524	usd
CY2024Q1	bicx	Common Stock Issued For Services Rendered Amount CommonStockIssuedForServicesRenderedAmount	149625	usd
CY2024Q1	bicx	Common Stock Issued In Connection With Issuance Of Promissory Notes Amount CommonStockIssuedInConnectionWithIssuanceOfPromissoryNotesAmount	40217	usd
CY2024Q1	bicx	Warrants Issued In Connection With Issuance Of Promissory Notes WarrantsIssuedInConnectionWithIssuanceOfPromissoryNotes	83552	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	48450	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1237463	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10868143	usd
CY2024Q2	bicx	Common Stock Issued For Services Rendered Amount CommonStockIssuedForServicesRenderedAmount	114779	usd
CY2024Q2	bicx	Common Stock Issued In Connection With Subscription Agreement Amount CommonStockIssuedInConnectionWithSubscriptionAgreementAmount	0	usd
CY2024Q2	bicx	Common Stock Issued In Connection With Conversion Of Promissory Notes And Accounts Payable Amount CommonStockIssuedInConnectionWithConversionOfPromissoryNotesAndAccountsPayableAmount	809284	usd
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	30480	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1233996	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11147596	usd
CY2024Q3	bicx	Common Stock Issued For Services Rendered Amount CommonStockIssuedForServicesRenderedAmount	561126	usd
CY2024Q3	bicx	Common Stock Issued In Connection With Issuance Of Promissory Notes Amount CommonStockIssuedInConnectionWithIssuanceOfPromissoryNotesAmount	67000	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	29261	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1513010	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-12003219	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8201731	usd
CY2023Q1	bicx	Common Stock Issued For Services Rendered Amount CommonStockIssuedForServicesRenderedAmount	63144	usd
CY2023Q1	bicx	Common Stock Issued In Connection With Issuance Of Promissory Notes Amount CommonStockIssuedInConnectionWithIssuanceOfPromissoryNotesAmount	6000	usd
CY2023Q1	bicx	Common Stock Issued In Connection With Subscription Agreement Amount CommonStockIssuedInConnectionWithSubscriptionAgreementAmount	300000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	16074	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1010586	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8827099	usd
CY2023Q2	bicx	Common Stock Issued For Services Rendered Amount CommonStockIssuedForServicesRenderedAmount	62291	usd
CY2023Q2	bicx	Common Stock Issued In Connection With Conversion Of Promissory Notes And Accounts Payable Amount CommonStockIssuedInConnectionWithConversionOfPromissoryNotesAndAccountsPayableAmount	361892	usd
CY2023Q2	bicx	Common Stock Issued In Connection With Subscription Agreement Amount CommonStockIssuedInConnectionWithSubscriptionAgreementAmount	600000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	15953	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-923547	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8710510	usd
CY2023Q3	bicx	Common Stock Issued For Services Rendered Amount CommonStockIssuedForServicesRenderedAmount	65125	usd
CY2023Q3	bicx	Common Stock Issued In Connection With Issuance Of Promissory Notes Amount CommonStockIssuedInConnectionWithIssuanceOfPromissoryNotesAmount	59580	usd
CY2023Q3	bicx	Warrants Issued In Connection With Issuance Of Promissory Notes WarrantsIssuedInConnectionWithIssuanceOfPromissoryNotes	176545	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	16205	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-867348	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9260403	usd
	us-gaap	Profit Loss ProfitLoss	-3984469	usd
	us-gaap	Profit Loss ProfitLoss	-2801481	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	740	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23163	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	200000	usd
	bicx	Derivative Liabilities Recognized In Connection With Issuance Of Promissory Notes DerivativeLiabilitiesRecognizedInConnectionWithIssuanceOfPromissoryNotes	26730	usd
	bicx	Record Right To Use Assets Per Asc842 RecordRightToUseAssetsPerAsc842	-225663	usd
	bicx	Project Support Income ProjectSupportIncome	0	usd
	bicx	Project Support Income ProjectSupportIncome	25817	usd
	us-gaap	Investment Company Dividend Distribution InvestmentCompanyDividendDistribution	4045	usd
	us-gaap	Investment Company Dividend Distribution InvestmentCompanyDividendDistribution	26164	usd
	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company licenses proprietary products and protocols to customers under licensing agreements that allow those customers to access the products and protocols in services they provide to their customers during the term of the license agreement. The timing and amount of revenue recognized from license agreements depends upon a variety of factors, including the specific terms of each agreement. Such agreements are reviewed for multiple performance obligations. Performance obligations can include amounts related to initial non-refundable license fees for the use of the Company’s products and protocols and additional royalties on covered services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company granted license and sub-license agreements for various regions or States in the United States allowing the licensee to market, distributes and sell solely in the defined license territory, as defined, the products provided by the Company. The agreements are granted for a defined period or perpetual and are effective as long as annual milestones are achieved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Terms for payments for licensee agreements vary from full cash payment to defined terms. In cases where license or sub-license fees are uncollected and deferred; the Company nets those uncollected fees with the deferred revenue for balance sheet presentation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company amortizes license fees over the shorter of the economic life of the related contract life or contract terms for each licensee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 1, 2019, the Company launched the UnCraveRx™ Weight Loss Management Program. Customers are charged a membership fee and are requested to pay for three training programs at inception. The payments are recorded as deferred revenue until earned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table presents the changes in deferred revenue, reflected as current and long term liabilities on the Company’s unaudited condensed consolidated balance sheet:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance as of December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Short term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Long term</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,045</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total as of December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,045</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net sales recognized</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,045 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Balance as of September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	47980	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	594025	usd
	bicx	Schedule Of Prepaid Expenses Table Textblock ScheduleOfPrepaidExpensesTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>S</strong><strong>eptember</strong><strong> 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid insurance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">30,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">18,511</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Prepaid subscription services</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">8,546</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">26,380</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">38,837</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">44,891</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	208709	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	133677	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	169443	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10945	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	208709	usd
	bicx	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P4Y7M6D
CY2023	bicx	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P1Y
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8143	usd
CY2024Q3	bicx	Accrual Of Interest And Loss On Contingency AccrualOfInterestAndLossOnContingency	402677	usd
CY2023Q4	bicx	Accrual Of Interest And Loss On Contingency AccrualOfInterestAndLossOnContingency	322000	usd
CY2023Q4	bicx	Payables To Customers Payroll PayablesToCustomersPayroll	0	usd
CY2024Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1288290	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	606750	usd
CY2024Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	77295	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-34338	usd
CY2023Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	121774	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	358882	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	355662	usd
	bicx	Royalty Agreements Description RoyaltyAgreementsDescription	each party would purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $3,000,000 at a purchase price of $15.00 per share (the “Purchase Price”), for a total of 200,000 shares of Common Stock; and (ii) the Company shall pay each (a) a total of $37.50 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the first (1st) day that the first unit of the treatment is sold (the “Initial Sales Date”) and ending on the third (3rd) anniversary of the Initial Sales Date; and (b) a total of $25.00 from the gross revenue derived from each of its weight loss treatments sold in the United States starting on the day following the third (3rd) anniversary of the Initial Sales Date and ending on the fifteenth (15th) anniversary of the Initial Sales Date (the “Royalty”)
	bicx	Expected Life Of Arrangement ExpectedLifeOfArrangement	P15Y
	us-gaap	Other Noncash Expense OtherNoncashExpense	7171200	usd
CY2024Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	121774	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	358882	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	355662	usd
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	183606	shares
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	180000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8674029	shares
	bicx	Share Based Goods And Nonemployee Services Transactions Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionsValuationMethodExpectedDividendRate	0.0000	pure
	bicx	First Payment Owed FirstPaymentOwed	0	usd
	bicx	Compensation For Services Descriptions CompensationForServicesDescriptions	As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a remuneration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	79492	usd
	bicx	Recognized Gain Loss On Contingency RecognizedGainLossOnContingency	-323184	usd

Files In Submission

Name	View Source	Status
0001477932-24-007148-index-headers.html	Edgar Link	pending
0001477932-24-007148-index.html	Edgar Link	pending
0001477932-24-007148.txt	Edgar Link	pending
0001477932-24-007148-xbrl.zip	Edgar Link	pending
bicx-20240930.xsd	Edgar Link	pending
bicx_10q.htm	Edgar Link	pending
bicx_ex311.htm	Edgar Link	pending
bicx_ex312.htm	Edgar Link	pending
bicx_ex321.htm	Edgar Link	pending
bicx_ex322.htm	Edgar Link	pending
bicx-20240930_cal.xml	Edgar Link	unprocessable
bicx-20240930_def.xml	Edgar Link	unprocessable
bicx-20240930_lab.xml	Edgar Link	unprocessable
bicx-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bicx_10q_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BICX
BioCorRx Inc. Stock $bicx

2024 Q4 Form 10-Q Financial Statement

#000147793224007148 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BICX BioCorRx Inc. Stock $bicx

2024 Q4 Form 10-Q Financial Statement

#000147793224007148 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BICX
BioCorRx Inc. Stock $bicx